Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.
The treatment of patients with relapsed and refractory Hodgkin lymphoma (HL), especially those who relapse after autologous stem cell transplantation, remains challenging. Patients with HL whose disease relapses after stem cell transplantation are rarely cured with current treatment modalities, and have a median survival of less than 3 years. Since no new drugs have been approved by the FDA for HL in more than three decades, there is a clear unmet medical need for drug development for this patient population. New treatment strategies that are based on targeting oncogenic signaling pathways are currently explored. This review will focus on emerging new treatment modalities that are currently under investigation for patients with relapsed classical HL.
Jona
Adam
A
Department of Lymphoma/Myeloma, M. D. Anderson Cancer Center, Houston, United States.
Younes
Anas
A
D000079963:Brentuximab Vedotin; D016503:Drug Delivery Systems; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D018796:Immunoconjugates / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use*; D007211:Indoles; D000077767:Panobinostat; D012008:Recurrence
D006877:Hydroxamic Acids; D018796:Immunoconjugates; D007155:Immunologic Factors; D007211:Indoles; D000079963:Brentuximab Vedotin; D000077767:Panobinostat